首页> The Journal of infectious diseases> Immunogenicity and Safety of Heterologous Omicron BA.1 and Bivalent SARS-CoV-2 Recombinant Spike Protein Booster Vaccines: A Phase 3 Randomized Clinical Trial.

Immunogenicity and Safety of Heterologous Omicron BA.1 and Bivalent SARS-CoV-2 Recombinant Spike Protein Booster Vaccines: A Phase 3 Randomized Clinical Trial.

导出 OA

翻译打印收藏纠错

第一作者： Chijioke,Bennett

第一单位： Novavax, Inc., Gaithersburg, Maryland, USA.

作者： Chijioke,Bennett ^[1] ; E Joy,Rivers ^[1] ; Wayne,Woo ^[1] ; Mark,Bloch ^[2] ; King,Cheung ^[3] ; Paul,Griffin ^[4] ; Rahul,Mohan ^[5] ; Sachin,Deshmukh ^[6] ; Mark,Arya ^[7] ; Oscar,Cumming ^[8] ; A Munro,Neville ^[9] ; Toni McCallum,Pardey ^[8] ; Joyce S,Plested ^[1] ; Shane,Cloney-Clark ^[1] ; Mingzhu,Zhu ^[1] ; Raj,Kalkeri ^[1] ; Nita,Patel ^[1] ; Agi,Buchanan ^[1] ; Alex,Marcheschi ^[1] ; Jennifer,Swan ^[1] ; Gale,Smith ^[1] ; Iksung,Cho ^[1] ; Gregory M,Glenn ^[1] ; Robert,Walker ^[1] ; Raburn M,Mallory ^[1]

作者单位： Novavax, Inc., Gaithersburg, Maryland, USA. ^[1] Holdsworth House Medical Practice and Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia. ^[2] Emeritus Research, Camberwell, Victoria, Australia. ^[3] Mater Misericordiae Ltd and University of Queensland, South Brisbane, Queensland, Australia. ^[4] Paratus Clinical Research Western Sydney, Blacktown, New South Wales, Australia. ^[5] Griffith University, Southport, Queensland, Australia. ^[6] Australian Clinical Research Network, Maroubra, New South Wales, Australia. ^[7] Novatrials, Newcastle, New South Wales, Australia. ^[8] AusTrials, Brisbane, Queensland, Australia. ^[9]

关键词 NVX-CoV2373 SARS-CoV-2 neutralizing antibody omicron BA.1 reactogenicity